Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages 8-15

  Trédan, Olivier ^a   Campone, Mario ^b   Jassem, Jacek ^c   Vyzula, Rostislav ^d   Coudert, Bruno ^e   Pacilio, Carmen ^f   Prausova, Jana ^g   Hardy Bessard, Anne Claire ^h   Arance, Ana ⁱ   Mukhopadhyay, Pralay ^j   Aloe, Alessandra ^j   Roché, Henri ^k  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b UMR INSERM U892 CNRS 6299   (France)

^c Klinika Onkologii I Radioterapii   (Poland)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^e Crlcc G Francois Leclerc   (France)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^h Clinique Armoricaine de Radiologie   (France)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j BRISTOL MYERS SQUIBB   (United States)

^k INSTITUT CLAUDIUS REGAUD   (France)

more..

Author keywords

Cetuximab; EGFR; Ixabepilone; Metastatic breast cancer; Triple negative

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMMONIA LYASE; BILIRUBIN; CETUXIMAB; CREATININE; HEMOGLOBIN; IXABEPILONE; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACNE; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; SENSORY NEUROPATHY; SEPSIS; SINUS ARRHYTHMIA; SKIN DISEASE; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VOMITING; ADENOCARCINOMA; ADJUVANT THERAPY; AGED; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPOTHILONES; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84920503993     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.07.007     Document Type: Article

References (42)

1. K.R. Bauer, M. Brown, and R.D. Cress Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 2007 1721 1728
2. S. Dawood Triple-negative breast cancer: epidemiology and management options Drugs 70 2010 2247 2258
3. K. Gelmon, R. Dent, and J.R. Mackey Targeting triple-negative breast cancer: optimising therapeutic outcomes Ann Oncol 23 2012 2223 2234
4. L.N. Harris, G. Broadwater, and N.U. Lin Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CLGB 9342 Breast Cancer Res 8 2006 R66
5. O. Metzger-Filho, A. Tutt, and E. de Azambuja Dissecting the heterogeneity of triple-negative breast cancer J Clin Oncol 30 2012 1879 1887
6. R. Dent, W.M. Hanna, and M. Trudeau Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Res Treat 115 2009 432 438
7. F. Heitz, P. Harter, and H.J. Lueck Triple-negative and HER2 overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases Eur J Cancer 45 2009 2792 2798
8. L.A. Carey, E.C. Dees, and L. Sawyer The triple-negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2007 2329 2334
9. C. Liedtke, C. Mazouni, and K.R. Hess Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 2008 1275 1281
10. R. Rouzier, C.M. Perou, and W.F. Symmans Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 2005 5678 5685
11. S. Tommasi, A. Mangia, and R. Lacalamita Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins Int J Cancer 120 2007 2078 2085
12. E. Rivera, J. Lee, and A. Davies Clinical development of ixabepilone and other epothilones in patients with advanced solid tumours Oncologist 13 2008 1207 1223
13. E.A. Perez, G. Lerzo, and X. Pivot Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistance to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 2007 3407 3414
14. E. Thomas, J. Tabernero, and M. Fornier Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 2007 3399 3406
15. H. Roché, L. Yelle, and F. Cognetti Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 2007 3415 3420
16. N. Denduluri, J.A. Low, and J.J. Lee Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 25 2007 3421 3427
17. X.B. Pivot, R.K. Li, and E.S. Thomas Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer Eur J Cancer 45 2009 2940 2946
18. E.A. Perez, T. Patel, and A. Moreno-Aspitia Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer Breast Cancer Res Treat 121 2010 261 271
19. H.S. Rugo, H. Roche, and E. Thomas Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies (abstract) Cancer Res 69 suppl 1 2008 (abstract 3057)
20. T. Holbro, G. Civenni, and N.E. Hynes The ErbB receptors and their role in cancer progression Exp Cell Res 284 2003 99 110
21. K.P. Siziopikou, R. Ariga, and K.E. Proussaloglou The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J 12 2006 360 362
22. G. Viale, N. Rotmensz, and P. Maisonneuve Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity Breast Cancer Res Treat 116 2009 317 328
23. B. Corkery, J. Crown, and M. Clynes Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Ann Oncol 20 2009 862 867
24. H. Nogi, T. Kobayashi, and M. Suzuki EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer Oncol Rep 21 2009 413 417
25. D. Gholam, A. Chebib, and D. Hauteville Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer Anticancer Drugs 18 2007 835 837
26. L.A. Carey, E. Mayer, and P.K. Marcom TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract) J Clin Oncol 2008 26 (abstract 1009)
27. L.A. Carey, H.S. Rugo, and P.K. Marcom TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer J Clin Oncol 30 2012 2615 2623
28. H. Nechushtan, H. Stainberg, and T. Peretz Preliminary results of a phase I/II combination of cetuximab and taxane for triple negative breast cancer patients (abstract) J Clin Oncol 27 2009 (abstract e12018)
29. P. Rivera, T. Filleron, and L. Gladieff Efficacy of cetuximab plus platinum agent in advanced, triple negative breast carcinoma: results of a retrospective analysis (abstract) J Clin Oncol 29 2011 (abstract e11581)
30. P.J. Real, A. Benito, and J. Cuevas Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L Cancer Res 65 2005 8151 8157
31. F.Y. Lee, A. Camuso, and S. Castaneda Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts (abstract) J Clin Oncol 24 2006 (abstract 12017)
32. F. Lee, M.N. Jure-Kunkel, and M.E. Salvati Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence Ther Adv Med Oncol 3 2011 11 25
33. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
34. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
35. D.W. Miles, A. Chan, and L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
36. N.J. Robert, V. Diéras, and J. Glaspy RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
37. J. O'Shaughnessy, D.J. Weckstein, and S.J. Vukelja Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer (abstract) Breast Cancer Res Treat 106 2007 (abstract 308)
38. J. Baselga, S. Stemmer, and A. Pego Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial (abstract) Cancer Res 70 suppl 2 2010 abstract PD01-01
39. B.D. Lehmann, J.A. Bauer, and X. Chen Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2011 2750 2767
40. M.N. Saleh, K.P. Raisch, and M.A. Stackhouse Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation Cancer Biother Radiopharm 14 1999 451 463
41. E. Perez, X. Pivot, and E. Vrdoljak A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer (abstract) Cancer Res 69 suppl 1 2008 (abstract 6140)
42. M.J. Duffy, P.M. McGowan, and J. Crown Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 131 2012 2471 2477